ESPR Esperion Therapeutics Inc

Esperion Therapeutics Inc is a pharmaceutical company focused on developing and commercializing oral, low-density lipoprotein cholesterol, or LDL-C, lowering therapies for the treatment of patients with elevated LDL-C.

As of 10/25/2021     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  06/26/2013
Outstanding shares:  28,277,493
Average volume:  907,430
Market cap:   $253,649,112
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    29664W105
ISIN:        US29664W1053
Valuation   (See tab for details)
PE ratio:   -0.77
PB ratio:   27.30
PS ratio:   4.08
Return on equity:   106.64%
Net income %:   -522.50%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy